Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hilpert, Felix
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC	Recruiting	3	1260	Europe	Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios	West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.	Breast Cancer Female	08/26	03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	Active, not recruiting	3	1684	Europe	Ribociclib 200Mg Oral Tablet, Kisqali	West German Study Group, Novartis, Genomic Health®, Inc.	Breast Cancer Female	07/27	07/27
MIROVA, NCT04274426: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer	Active, not recruiting	2	136	Europe	Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine	AGO Research GmbH	Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	12/25	12/26
WoO, NCT04644289: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC	Recruiting	2	60	Europe	olaparib, Lynparza, durvalumab, Imfinzi	AGO Research GmbH	Epithelial Ovarian Cancer	01/28	06/28